ION 581
Alternative Names: ION 581; UBE3A gene expression stimulant; UBE3A-ATS targeting oligoneucleotidesLatest Information Update: 28 Jun 2022
At a glance
- Originator Baylor College of Medicine; Isis Pharmaceuticals
- Developer Baylor College of Medicine; Ionis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Genetic transcription inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Angelman syndrome